US20050238692A1 - Biomedical adhesive - Google Patents
Biomedical adhesive Download PDFInfo
- Publication number
- US20050238692A1 US20050238692A1 US10/515,164 US51516405A US2005238692A1 US 20050238692 A1 US20050238692 A1 US 20050238692A1 US 51516405 A US51516405 A US 51516405A US 2005238692 A1 US2005238692 A1 US 2005238692A1
- Authority
- US
- United States
- Prior art keywords
- group
- bulk material
- groups
- carboxy
- activated compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- FMKQQDQRIHIWBS-UHFFFAOYSA-N CC(=O)N1C=CN=C1.CC(=O)N1OC(=O)N(C)C1=O.CC(=O)OC1=C(F)C(F)=C(F)C(F)=C1F.CC(=O)OC1=CC=C([N+](=O)[O-])C=C1.CC(=O)OC1=CN=NC1C1=CC=C([N+](=O)[O-])C=C1.CC(=O)ON1C(=O)CCC1=O.CC(=O)ON1N=NC2=C(C=CC=C2)C1=O.CC(=O)ON1N=NC2=C1C=CC=C2.[CH2-]C#CC#CC#CC#CC#CC(C)#COC(=O)OC(C)=O Chemical compound CC(=O)N1C=CN=C1.CC(=O)N1OC(=O)N(C)C1=O.CC(=O)OC1=C(F)C(F)=C(F)C(F)=C1F.CC(=O)OC1=CC=C([N+](=O)[O-])C=C1.CC(=O)OC1=CN=NC1C1=CC=C([N+](=O)[O-])C=C1.CC(=O)ON1C(=O)CCC1=O.CC(=O)ON1N=NC2=C(C=CC=C2)C1=O.CC(=O)ON1N=NC2=C1C=CC=C2.[CH2-]C#CC#CC#CC#CC#CC(C)#COC(=O)OC(C)=O FMKQQDQRIHIWBS-UHFFFAOYSA-N 0.000 description 3
- SIFCHNIAAPMMKG-UHFFFAOYSA-N CC(=O)ON1C(=O)CCC1=O Chemical compound CC(=O)ON1C(=O)CCC1=O SIFCHNIAAPMMKG-UHFFFAOYSA-N 0.000 description 3
- XOVKZVDIWVQFCQ-UHFFFAOYSA-N CC.CC.CC(=O)CC(C)[Y].CCC(=O)CC(C)[Y].CCC(=O)CC(C)[Y].COC(=O)CC(C)[Y] Chemical compound CC.CC.CC(=O)CC(C)[Y].CCC(=O)CC(C)[Y].CCC(=O)CC(C)[Y].COC(=O)CC(C)[Y] XOVKZVDIWVQFCQ-UHFFFAOYSA-N 0.000 description 1
- DXNPRDMHBRUZRW-DEPNEFQXSA-N CCCCC.[3H]CCCCC.[3H]CCCCC.[3H]CCCCC.[3H]CCCCC.[3H]CCCCCC.[3H]CCCCCC.[3H]CCCCCCC.[3H]CCCCCCCC.[3H]CCCCCCCC.[3H]CCCCCCCC.[3H]CCCCCCCC.[3H]CCCCCCCCCCCCCCCCCCCCCCCC[3H].[3H]CCCCCCCCCCCCCC[3H].[3H]CCCCCCCCCCCCCC[3H] Chemical compound CCCCC.[3H]CCCCC.[3H]CCCCC.[3H]CCCCC.[3H]CCCCC.[3H]CCCCCC.[3H]CCCCCC.[3H]CCCCCCC.[3H]CCCCCCCC.[3H]CCCCCCCC.[3H]CCCCCCCC.[3H]CCCCCCCC.[3H]CCCCCCCCCCCCCCCCCCCCCCCC[3H].[3H]CCCCCCCCCCCCCC[3H].[3H]CCCCCCCCCCCCCC[3H] DXNPRDMHBRUZRW-DEPNEFQXSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F290/00—Macromolecular compounds obtained by polymerising monomers on to polymers modified by introduction of aliphatic unsaturated end or side groups
- C08F290/02—Macromolecular compounds obtained by polymerising monomers on to polymers modified by introduction of aliphatic unsaturated end or side groups on to polymers modified by introduction of unsaturated end groups
- C08F290/06—Polymers provided for in subclass C08G
- C08F290/062—Polyethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/34—Macromolecular materials
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F290/00—Macromolecular compounds obtained by polymerising monomers on to polymers modified by introduction of aliphatic unsaturated end or side groups
- C08F290/02—Macromolecular compounds obtained by polymerising monomers on to polymers modified by introduction of aliphatic unsaturated end or side groups on to polymers modified by introduction of unsaturated end groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/14—Eye parts, e.g. lenses, corneal implants; Implanting instruments specially adapted therefor; Artificial eyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/16—Materials or treatment for tissue regeneration for reconstruction of eye parts, e.g. intraocular lens, cornea
Definitions
- the present invention relates to a biomedical adhesive. Particularly, it relates to a ready-to-use adhesive for an organic or inorganic biocompatible bulk material in biological applications.
- One suitable use of the adhesive is binding a corneal onlay or inlay under ambient conditions to the corneal basement membrane or corneal stromal tissue.
- Tissue is defined as any part of the body, living or dead.
- a biomedical device that can be glued directly to tissue and attains sufficient interfacial bond strength is attractive because it may obviate the need for surgical methods such as suturing.
- Useful applications include the adhesion of drug delivery devices to the epidermis, the gluing of anti-adhesion barriers for surgery and the adhesion of synthetic onlays or inlays to the cornea.
- Conventional surgical adhesives are often not suitable for a wide range of adhesive applications.
- cyanoacrylates and fibrin glues are used clinically as soft tissue adhesives.
- U.S. Pat. No. 5,354,336 describes a method for sealing lenticules onto a corneal surface comprising the steps of placing the lenticule to the correct position, applying a polymerizable collagen composition onto the lenticule and the corneal surface to form a collagen coating over the lenticule and the corneal surface and polymerizing the coating in the presence of an initiator thereby sealing the lenticule onto the corneal surface.
- glues have not yet proven satisfactory mainly because of severe handling problems. For example, the surgeon always has to mix the glue components shortly prior to use.
- Biomedical adhesives may be given different names, including “bioadhesive”, “biological adhesive” and “surgical adhesive” among others.
- bioadhesive biocompatible adhesive
- biological adhesive biological adhesive
- surgical adhesive among others.
- body material is used in this specification to refer to biocompatible organic or inorganic material. This includes for example polymers from which biomedical devices are formed, prostheses, etc.
- the bulk material would usually be a solid phase.
- the present invention therefore relates to a biomedical adhesive comprising multifunctionally activated functional groups.
- a method for bonding a bulk material to a nucleophilic or electrophilic surface including attaching a multifunctionally activated functional group to the bulk material and then contacting the functional group with the nucleophilic surface under conditions permitting covalent linkage between the surface and the functional group.
- the compound and the surface can be either electrophilic or nucleophilic, as long as each is the opposite of the other so as to enable reaction between them—such a pair of reactive groups may be called “corresponding” (eg, an activated ester and an amino group).
- the conditions are selected to be as convenient as possible.
- the temperature range is preferably between 0° C. and 60° C., most preferably body temperature (ie, about 37° C.). Ambient pressure is suitable.
- the invention also provides a bioadhesive attached to a bulk material for bonding the bulk material to a biological surface, the bioadhesive comprising a multifunctionally activated compound reactable with nucleophilic or electrophilic functional groups.
- the multifunctionally activated functional group is preferably an activated ester or amide.
- the invention also provides a bioadhesive covalently linking a bulk material with a biological surface, the adhesive being formed by the curing of a multifunctionally activated functional group.
- the invention also provides a biomedical device for attaching to a biological surface including a biocompatible organic or inorganic bulk material to which a multifunctionally activated compound has been bonded.
- the invention is also directed towards a method of preparing a device comprising a bulk material combined with a bioadhesive which may be stored anhydrously prior to use, comprising attaching the multifunctionally activated functional group to the bulk material and then dehydrating the device.
- the invention also provides a process for applying a bioadhesive to a surface of a biomedical device comprising the steps of
- the invention is particularly directed towards a bioadhesive for in vivo use.
- the invention can be used to adhere, for example, synthetic materials to which the bioadhesive multifunctionally activated compound is attached to any appropriate nucleophilic or electrophilic surface of an animal (including humans).
- a common nucleophilic surface to which such articles may be attached is collagen, or any other lysine-rich polypeptide (whether natural or synthetic).
- Collagen may confer other properties on the biomedical device useful or desirable for its intended purpose.
- Collagen may be bonded to the biomedical device of the invention by the same surface functional groups as bind the multifunctionally activated compound or otherwise.
- the invention has particular application to biomedical devices made from a bulk material which is strongly hydrophobic. Such materials are known to be difficult to adhere in a biological environment.
- hydrophobic surfaces may first be treated by the addition of surface functional groups (such as aldehydes) by known processes (such as plasma deposition).
- Suitable multifunctionally activated functional groups include carboxy derivative groups, such as, for example, carboxylic halides, for example —COCl or —COBr; carboxylic anhydrides; lactones; carboxylic amides; or preferably carboxylic esters.
- carboxy derivative groups such as, for example, carboxylic halides, for example —COCl or —COBr; carboxylic anhydrides; lactones; carboxylic amides; or preferably carboxylic esters.
- a preferred group of carboxy derivative groups are esters, in particular activated esters or amides.
- the reactive groups may be selected from a class of esters, which are highly reactive towards nucleophiles. Active esters or other reactive groups derived from carboxylic acids or amides undergo elimination reactions with nucleophiles to form stable adducts as follows:
- General reaction (1) describes the elimination reaction of nucleophiles (Nu) with an active ester (AE).
- General reaction (2) describes the elimination reaction of nucleophiles (Nu) with a reactive group (XG). in which
- the reactive groups can be in the form of a multifunctional dendritic polymer, a multifunctionalized comb like polymer, the terminating ends of a linear polymer or other multifunctional polymer where there is at least one reactive group per polymer chain as follows:
- bioadhesive that supports or inhibits cell growth, or is biodegradable or non-biodegradable.
- the bioadhesives can also contain other materials, such as inert biocompatible fillers, to improve the viscosity and to result in porosity after leaching.
- An activated ester or amide is, for example, a radical of formula
- a preferred carboxy derivative group according to the invention is an activated ester group of formula (g), (e) or, in particular, of formula (h).
- Multifunctionally activated compounds are, for example, compounds of formula R 13 -D-R 12 (j),
- bivalent organic radicals D are, for example, an optionally branched C 1 -C 12 -alkylene; a radical of dendrimer or star bust polymer; a radical of a polyethylene glycol; a radical of a polyvinyl alcohol, for example, a polyvinyl alcohol with pendant polymerisable groups as described in WO 96/24075; or a radical of a hyperbranched polyester resin as described by M. Johansson and A. Hult in Journal of Coatings Technology, 67, No. 849, 35 (1995).
- D is preferably a bivalent radical of a polyethylene glycol, for example a radical of formula —CH 2 —CH 2 —(O—CH 2 —CH 2 ) f —, wherein f is an integer of, for example, from 2 to 250.
- R 12 is a carboxy derivative group, wherein the above given meanings and preferences apply.
- R 13 is independently preferably a carboxy derivative group, wherein the above given meanings and preferences apply. Most preferably, R 12 and R 13 are identical.
- the multifunctionally activated compound is polyethylene glycol that is di-substituted with succinimidyl propionate, succinimidyl succinate or succinimidyl succinimide, or the known derivatives of these functional groups.
- the method of attaching a multifunctional compound of formula (O) to a bulk material surface provided with a natural or synthetic polymer comprising co-reactive functional groups depends on the nature of the reactive groups being present in compound (j) and at the natural or synthetic polymer.
- the reactions are known per se, for example, from textbooks of organic chemistry.
- a compound of formula (j) with a carboxy, amide or ester group R 13 is to be coupled to a natural or synthetic polymer containing amino, thiol or hydroxy groups
- the reaction may be carried out under the conditions that are customary for ester or amide formation. It is preferred to carry out the esterification or amidation reaction in the presence of an activating agent, for example N-ethyl-N′-(3-dimethyl aminopropyl)carbodiimide (EDC), N-hydroxy succinimide (NHS) or N,N′-dicyclohexyl carbodiimide (DCC).
- an activating agent for example N-ethyl-N′-(3-dimethyl aminopropyl)carbodiimide (EDC), N-hydroxy succinimide (NHS) or N,N′-dicyclohexyl carbodiimide (DCC).
- a compound of formula (O) with an anhydride group R 13 is to be coupled to a natural or synthetic polymer containing amino, thiol or hydroxy groups
- the reaction may be carried out as described in organic textbooks, for example in an aprotic solvent, for example one of the above-mentioned aprotic solvents, at a temperature from room temperature to about 100° C.
- reaction may be carried out, for example, at room temperature or at elevated temperature, for example at about 20 to 100° C., in an aprotic medium.
- a compound of formula (j) with an isocyanato group R 13 is to be coupled to a natural or synthetic polymer containing amino or hydroxy groups
- the reaction may be carried out in an inert organic solvent such as acetonitrile, an optionally halogenated hydrocarbon, for example petroleum ether, methylcyclohexane, toluene, chloroform, methylene chloride and the like, or an ether, for example diethyl ether, tetrahydrofurane, dioxane, or a more polar solvent such as DMSO, DMA, N-methylpyrrolidone or even a lower alcohol or water, at a temperature of from 0 to 100° C., preferably from 0 to 50° C.
- an inert organic solvent such as acetonitrile, an optionally halogenated hydrocarbon, for example petroleum ether, methylcyclohexane, toluene, chloroform, methylene chloride and the like, or
- a catalyst for example a tertiary amine such as triethylamine or tri-n-butylamine, 1,4-diazabicyclooctane, or a tin compound such as dibutyltin dilaurate or tin dioctanoate.
- a catalyst for example a tertiary amine such as triethylamine or tri-n-butylamine, 1,4-diazabicyclooctane, or a tin compound such as dibutyltin dilaurate or tin dioctanoate.
- the reaction of the isocyanato groups with amino groups may also be carried out in an aqueous solution in the absence of a catalyst. It is advantageous to carry out the above reactions under an inert atmosphere, for example under a nitrogen or argon atmosphere.
- a compound of formula (j) with an epoxy group R 13 is to be coupled to a natural or synthetic polymer containing amino, thiol or hydroxy groups
- the reaction may be carried out, for example, at room temperature or at elevated temperature, for example at about 20 to 100° C., in an aprotic medium using a base catalyst, for example Al(O—C 1 -C 6 -alkyl) 3 or Ti(O—C 1 -C 6 -alkyl) 4 .
- the bulk material forms a biomedical device.
- the device may be obtainable by a process comprising the steps of
- Examples of bulk materials that may be coated according to the process of the invention are natural or synthetic organic polymers, or laminates, composites or blends of said materials.
- Some examples of polymers are polyaddition and polycondensation polymers (polyurethanes, epoxy resins, polyethers, polyesters, polyamides, polycarbonates and polyimides); vinyl polymers (polyacrylates, polymethacrylates, polystyrene, polyethylene, polyacrylamides and halogenated derivatives thereof, polyvinyl acetate and polyacrylonitrile); elastomers (silicones, polybutadiene and polyisoprene); or modified or unmodified biopolymers (collagen, cellulose, chitosan and the like).
- Another preferred group of bulk materials are those conventionally used for the manufacture of biomedical devices, e.g. contact lenses, intraocular lenses or artificial cornea, which are not hydrophilic per se.
- Such materials are known to the skilled artisan and may comprise for example polysiloxanes, perfluoropolyethers (PFPE), fluorinated poly(meth)acrylates or equivalent fluorinated polymers derived e.g.
- fluorinated polyolefines such as fluorinated ethylene propylene, or tetrafluoroethylene, preferably in combination with specific dioxols, such as perfluoro-2,2-dimethyl-1,3-dioxol.
- suitable bulk materials are e.g.
- Teflon AF materials such as Teflon AF 1600 or Teflon AF 2400 which are copolymers of about 63 to 73 mol % of perfluoro-2,2-dimethyl-1,3-dioxol and about 37 to 27 mol % of tetrafluoroethylene, or of about 80 to 90 mol % of perfluoro-2,2-dimethyl-1,3-dioxol and about 20 to 10 mol % of tetrafluoroethylene.
- biocompatible polymers are those being conventionally used for the manufacture of biomedical devices, e.g. contact lenses, which are hydrophilic per se, since hydrophilic groups, e.g. carboxy, carbamoyl, sulfate, sulfonate, phosphate, amine, ammonium or hydroxy groups, are inherently present in the material.
- hydrophilic groups e.g. carboxy, carbamoyl, sulfate, sulfonate, phosphate, amine, ammonium or hydroxy groups
- Such materials are known to the skilled artisan and comprise for example polyhydroxyethyl acrylate, polyhydroxyethyl methacrylate (HEMA), polyvinyl pyrrolidone (PVP), polyacrylic acid, polymethacrylic acid, polyacrylamide, poly-N,N-dimethyl acrylamide (DMA), polyvinyl alcohol, copolymers for example from two or more monomers from the group hydroxyethyl acrylate, hydroxyethyl methacrylate, N-vinyl pyrrolidone, acrylic acid, methacrylic acid, acrylamide, N,N-dimethyl acrylamide, vinyl alcohol, vinyl acetate and the like, polyalkylene glycols such as polyethylene glycols, polypropylene glycols or polyethylene/polypropylene glycol block copolymers.
- HEMA polyhydroxyethyl methacrylate
- PVP polyvinyl pyrrolidone
- polyacrylic acid polymethacrylic acid
- Typical examples are e.g. Polymacon, Tefilcon, Methafilcon, Deltafilcon, Bufilcon, Phemfilcon, Ocufilcon, Focofilcon, Etafilcon, Hefilcon, Vifilcon, Tetrafilcon, Perfilcon, Droxifilcon, Dimefilcon, Isofilcon, Mafilcon, Nelfilcon or Atlafilcon.
- An even more preferred group of bulk materials are, for example, porous polymers with improved wettability and cell growth ability as described in U.S. Pat. No. 6,015,609, WO 97/35906, WO 97/35905, WO 00/49058 or in WO 00/15686.
- Polymers incorporating charged units or zwitterions are also useful in this invention, and the contents of that specification are herein incorporated by reference. Additional examples are provided in European Patent Application no. 02011173.8, the contents of which are herein incorporated by reference.
- PFPE macromonomers and the synthesis of polymers therefrom are known e.g. from PCT applications WO 96/31546 or WO 97/35906.
- the bulk material network can, if desired, be reinforced by addition of a crosslinking agent, that is not a PFPE polymer, for example by a polyunsaturated crosslinking comonomer.
- a crosslinking agent that is not a PFPE polymer
- polyunsaturated crosslinking comonomers are allyl (meth)acrylate, lower alkylene glycol di(meth)acrylate, poly(lower alkylene) glycol di(meth)acrylate, lower alkylene di(meth)acrylate, divinyl ether, divinyl sulfone, di- and trivinylbenzene, trimethylolpropane tri(meth)acrylate, pentaerythritol tetra(meth)acrylate, bisphenol A di(meth)acrylate, methylenebis(meth)acrylamide, triallyl phthalate and diallyl phthalate.
- the preferred bulk materials of the invention may be obtained by copolymerizing one or more PFPE macromonomers, one or more charged monomers or a suitable precursor thereof and optional further comonomers and/or additives to afford a transparent polymer in the presence of a suitable initiator.
- Standard methods well known in the art for effecting polymerization may be utilized, with free radical polymerization being preferred.
- Free radical polymerization can be simply carried out by radiating (using ultra-violet light) monomer mixtures containing a UV initiator, such as benzoin methylether, in an appropriate container or vessel. The mixture is irradiated for a sufficient time to enable polymerization between monomers to take place.
- thermal initiation using a thermal initiator such as azobisisobutyronitrile can be employed.
- a precursor of the zwitter-ionic monomer is used, the copolymer after the irradiation may be treated with a suitable reagent in order to convert the precursor units into zwitter-ionic units.
- the polymerization mixture can be converted to a polymer neat or in the presence of one or more solvents. While the structure of the components of the polymerization mixture has the most significant effect on the resulting modulus, the choice of solvent and comonomer also has an effect.
- Useful solvents include those selected from the following classes: esters, alcohols, ethers, and halogenated solvents. Fluorinated solvents are particularly useful and their use in combination with other solvents (in ratios varying from 1:9 to 9:1) from the classes above is especially desirable. Solvent concentrations of between 0-70% w/w, particularly 30-80% w/w, especially 55% in the polymerization mixture are desirable.
- Preferred solvents include acetates, particularly isopropyl acetate and tert-butyl acetate, 2-(trifluoromethyl)-2-propanol, chlorofluoroalkanes, particularly trichlorotrifluoroethane, and perfluorinated alkanes, such as perfluoro-1,3-dimethylcyclohexane, 2,2,3,3-tetrafluor-1-propanol, 2′,3′,4′,5′,6′-pentafluoroacetophenone, 1,1,1-trifluoro-3,4-pentadione, 2′,3′,4′,5′,6′-pentafluorobenzyl alcohol and the like.
- a particular preferred solvent is water or an aqueous solution comprising, for example, one or more organic solvents, for example a C 1 -C 4 -alkanol such as methanol or ethanol, or a fluorinated alkane.
- Water may be 1 to 70% w/w, preferably 2 to 50% w/w and particularly preferably 3 to 30% w/w, in each case based on the entire formulation.
- the bulk materials may form porous substrates. Porosity may be provided by the inherent porosity of the material. Alternatively, pores may be introduced into the polymers by various procedures such as those disclosed in PCT applications WO 00/15686.
- a polar solvent for example water, a C 1 -C 4 -alkanol, and/or a surfactant, preferably a fluorinated surfactant, may be incorporated into the polymerization mixture.
- a polar solvent for example water, a C 1 -C 4 -alkanol, and/or a surfactant, preferably a fluorinated surfactant
- a surfactant preferably a fluorinated surfactant
- the use of surfactants is an effective means of controlling the size and density of the pores.
- Non-ionic surfactants containing fluorine are preferred.
- Particularly preferred surfactants include commercially available fluorinated surfactants such as Zonyl (DuPont) and Fluorad (3M).
- Suitable bulk materials are those obtainable by copolymerizing one or more macromonomers comprising at least one PFPE unit, wherein the above-given meanings and preferences apply, and at least one zwitter-ionic monomer or a precursor thereof, wherein again the above-given meanings and preferences apply, in an aqueous solution and, if a zwitter-ionic monomer precursor has been used, converting the precursor units into charged units after the copolymerization reaction.
- a particular preferred reaction medium in this context is an aqueous solution comprising a C 1 -C 4 -alkanol, in particular methanol or ethanol, a fluorinated surfactant and optionally a fluorinated alkane.
- the surface of the bulk material may inherently contain functional groups or may be provided with covalently attached functional groups, for example, by plasma deposition, particularly if it is hydrophobic.
- the method of coating a surface by plasma deposition is known to the skilled artisan and is described in, e.g. WO 98/52620 and WO 00/29548.
- Typical examples of reactive groups being introduced to the surface of the bulk material by plasma surface preparation include aldehyde groups, amino groups, hydroxy groups, carboxy groups, carbonyl groups, sulfonic acid groups, sulfonyl chloride groups and groups able to be replaced by amino or hydroxy groups, such as halo groups.
- Aldehyde groups, thiol groups, amino groups, hydroxy groups and carboxy groups are preferred.
- Examples of the natural or synthetic polymer used are cell-adhesive glycoproteins like collagens (various types), fibronectin, vitronectin, laminin, poly(ethyl imine), amino dextran, PAMAM dendrimers, poly(allyl amine), poly(vinyl alcohol), poly(arylic acid) and poly(methacrylic acid). Collagen and collagen-like proteins are preferred.
- the coupling of cell-adhesive glycoproteins to plasma polymers covalently bound to the underlying bulk material is known and described, for example, in WO 00/29548.
- biomedical devices according to the invention comprising a preferred bulk material, that is a bulk material obtainable by copolymerizing a macromonomer comprising at least one PFPE unit and a zwitter-ionic monomer in an aqueous solution, offer the additional advantage, that unlike other hydrophobic materials, for example those disclosed in WO 00/15686, they may be hydrated very easily. Accordingly, the biomedical devices of the invention may be dehydrated after their preparation and stored for extended periods without loss of adhesive activity.
- Such a biomedical device for example an onlay
- biomedical devices such as corneal inlays and onlays or lenticules
- a polymer as described above, and then dried and stored in anhydrous conditions. This maintains the multifunctionally activated compounds' unreacted reactive groups such that they can bond to tissue upon implantation or affixation of the device to tissue, after re-hydration to increase polymer chain mobility.
- the biomedical devices of the present invention such as in particular corneal onlays and inlays may be fixed on the cornea by just placing the device in intimate contact with the corneal tissue for a certain time period, for example for about 5 to 30 minutes and especially for 10 to 20 minutes.
- Such onlays and inlays are easier to handle, since the use thereof does not involve, for example, a premixing of glue components or time pressure upon the surgeon due to specific curing times of the glue components.
- no tedious removal of excess glue after fixing onto the cornea is necessary, and the previous problem of inhibition of overgrowth by glue residues does not exist.
- the cornea is previously prepared for the attachment of an onlay, for example, by removing the epithelial cell layers of the cornea by scraping and/or washing the eye, for example, with ethanol/water mixtures.
- the cornea surface and the lenticule are dried with surgical sponges or the like. It is desirable to minimise the fluid and air between the lenticule and the cornea surface. Excess fluid and air may be removed by applying pressure across the membrane using a rolling action with a surgical instrument.
- Such onlays provide a new route towards implanting a corneal onlay onto a cornea which is easy to perform, does not affect the wearers vision, and is safe.
- a mechanically stable fixation of the implant on the cornea is obtained which lasts for a period of time sufficient for normal biological function to recover after surgery. This may include the chance to allow the epithelial cells to recover, grow over the implant and thus fix it in a persistent manner.
- the invention is particularly suitable for corneal inlays where cell growth ability is less important.
- Cell growth ability may be impeded by higher charged unit content, such as over 10% w/w, although this may be overcome by surface modification of the inlay (eg collagen attachment).
- the inlay may be implanted using known techniques. For example, an incision may be made in the stroma, into which the re-hydrated inlay is placed. The inlay then attaches to the stroma through reaction of the re-activated functional groups of the multifunctionally activated compound with no additional material being required. Polymers with charged unit content of around 20% are useful for this application.
- the following formulation was prepared in a glass vial furnished with a stirrer.
- the components were added in order of decreasing hydrophilicity and mixed well, prior to the addition of the photoinitiator.
- the photoinitiator (Darocur 1173)
- the mixing was continued for a further five minutes.
- the resulting solution was then placed in polypropylene moulds and polymerised for 3 hours under the irradiation of broad spectrum UV lamps. (1 mW/cm ⁇ 2 ).
- the polymers (20 mm diameter disc 50 to 250 microns thick) were removed from the mold and placed through a general extraction procedure to remove any unpolymerised components.
- This procedure consists of a 2 ⁇ 24 h soaking in a fluorinated solvent such as Vertrel XF (DuPont), TCTFE (Aldrich) or HFE 7100 (3M), then 2 ⁇ 24 hr immersion in isopropyl acetate and subsequent immersion for 2 ⁇ 24 h in methanol.
- the polymers were then hydrated by a graded solvent change from methanol to ethanol (2 ⁇ 24 hr), 75% ethanol/water (2 ⁇ 24 hr), 50% ethanol/water (2 ⁇ 24 hr), 25% ethanol/water (2 ⁇ 24 hr), then pure water or saline (2 ⁇ 24 hr). This assists in extracting unpolymerised monomers/solvents/surfactants.
- Part A consisted of (parts by weight): PFPE macromonomer #1 4.5 PFPE macromonomer #2 0.5 Ethanol 2.5 PFDMCH 3.0
- Part B consisted of a 50% (w/w) solution of [2-(methacryloyloxy)ethyl]dimethyl(3-sulfopropyl)-ammonium inner salt (zwitterion) in water.
- Component Amount Part A 1.749 Part B 0.143
- Surfactant Zonyl FSK 0.1841 Darocur 1173 0.0024 EWC (%) 27.5
- Optical Clarity 95.6 %
- EWC Equilibrium water contents
- porosity measurements are measured as reported by Chaouk H. et al, J. Appl. Polym. Sci., 2001, 80, 1756.
- Optical haze (%) is measured using a Gardner PG-5500 digital photometric unit.
- Optical clarity is calculated by subtracting optical haze from 100%.
- Example 1 The formulation of Example 1 was covalently coated, both sides, with type 1 collagen according to the procedure disclosed in WO 00/29548.
- the collagen coated materials were then exchanged from phosphate buffered saline (PBS) to MilliQ water, then 100% ethanol and finally acetonitrile.
- the acetonitrile was then replaced by dry acetonitrile.
- 250 ⁇ l of poly(ethylene glycol) di(succinimidyl propionate) solution 582 mg, Shearwater Polymers, dissolved in 1.2 ml of dry acetonitrile) were added to each of the acetonitrile equilibrated collagen coated self-hydrating polymer samples in separate vials.
- samples 1,2,3 were evaporated to dryness using a rotary evaporator.
- Another 3 samples (4,5,6) had the excess crosslinker solution removed with a pipette. Dry acetonitrile (2 ml) was added to these vials and they were gently shaken before removing excess acetonitrile solution with a pipette.
- the three samples (samples 4,5,6) were then evaporated to dryness using a rotary evaporator. All samples were stored under vacuum over P 2 O 5 until used, in this case seven days later, although lenticules made in this manner could be stored much longer.
- the dried surface-modified lenticules of Example 45 are hydrated by placing them in water.
- the hydration process may be performed using PBS instead of water or aqueous mixtures.
- the lenticules were surface dried using lint-free tissue paper and then placed on a freshly debrided bovine cornea. Excess fluid and bubbles were expelled from under the lenticule by gently wiping across the anterior surface of the lenticule.
- the lenticule was allowed to cure for 15 to 19 minutes before the adhesion was assessed using a vacuum tester (a detachment threshold>5.5 means that the adhesion is greater than what was able to be tested using the vacuum tester): hydration time cure time detachment Sample (minutes) (minutes) threshold 1 2 16 >5.5 2 2 15 >5.5 3 2 15 >5.5 4 2 15 >5.5 5 2 17 3.5 6 2 19 >5.5
- Poly(ethylene glycol) di(succinimidyl propionate) (50 mg, Shearwater Polymers) was dissolved in water for irrigation (125 ⁇ l, Baxter products) within 30 seconds by vigorous mixing.
- a hydrated but surface dried double sided collagen coated perfluoropolyether lenticule was cast in a contact lens mould.
- the concave cup of the lenticule was filled with poly(ethylene glycol) di(succinimidyl propionate) solution. After two minutes the solution was removed by pipettor and the excess poly(ethylene glycol) di(succinimidyl propionate) solution was removed by washing the modified lenticule for 4 minutes in water (for irrigation, 25 ml, Baxter products).
- the lenticules were then surface dried using lint free tissue paper.
- the modified lenticules were then placed on a freshly debrided feline cornea. Excess fluid and bubbles were expelled from under the lenticule by gently wiping across the face of the lenticule.
- the lenticules were allowed to cure for 10 minutes before antibacterial cream is applied to the eyes and the cat is allowed to gain consciousness.
Abstract
The biomedical adhesives of the invention provide a reactive surface to adhere or crosslink to tissue and may be used, for example, as ready-to-use corneal onlay in ophthalmic surgery. The invention provides a method for bonding a bulk material to a corresponding nucleophilic or electrophilic surface including attaching a multifunctionally activated bulk material compound to the bulk material and contacting a functional group of the compound with the surface under conditions permitting covalent linkage between the bulk material and the functional group.
Description
- The present invention relates to a biomedical adhesive. Particularly, it relates to a ready-to-use adhesive for an organic or inorganic biocompatible bulk material in biological applications. One suitable use of the adhesive is binding a corneal onlay or inlay under ambient conditions to the corneal basement membrane or corneal stromal tissue.
- It is desirable in many applications, especially in the biomaterial and medical field to adhere biomaterials and other biocompatible materials or devices to tissue. Tissue is defined as any part of the body, living or dead. A biomedical device that can be glued directly to tissue and attains sufficient interfacial bond strength is attractive because it may obviate the need for surgical methods such as suturing. Useful applications include the adhesion of drug delivery devices to the epidermis, the gluing of anti-adhesion barriers for surgery and the adhesion of synthetic onlays or inlays to the cornea. Conventional surgical adhesives are often not suitable for a wide range of adhesive applications. Currently cyanoacrylates and fibrin glues are used clinically as soft tissue adhesives. However the brittleness of the cured adhesives, the potential toxicity of their biodegradation products and the lack of control over cure time are the major drawbacks of cyanoacrylates. Slow curing, poor mechanical strength and infection risk are disadvantages of fibrin-based glues.
- A variety of different methods for the bonding of devices to tissue have been disclosed in the prior art. For example, U.S. Pat. No. 5,354,336 describes a method for sealing lenticules onto a corneal surface comprising the steps of placing the lenticule to the correct position, applying a polymerizable collagen composition onto the lenticule and the corneal surface to form a collagen coating over the lenticule and the corneal surface and polymerizing the coating in the presence of an initiator thereby sealing the lenticule onto the corneal surface. However said glues have not yet proven satisfactory mainly because of severe handling problems. For example, the surgeon always has to mix the glue components shortly prior to use. Once the premixing has taken place, only a limited time period is available for using the glue depending on the glue's specific curing time; this puts time-pressure on the surgeon. Following the attachment of the lenticule onto the cornea, excessive glue has to be removed carefully otherwise glue residues may inhibit the normal function of biological tissue. Further disadvantages of the known glues are, for example, insufficient mechanical stability and adhesive duration.
- Reference to any prior art in the specification is not, and should not be taken as, an acknowledgment or any form of suggestion that this prior art forms part of the common general knowledge in Australia or any other country.
- It will be understood that the term “comprises” or its grammatical variants as used in this specification and claims is equivalent to the term “includes” and is not to be taken as excluding the presence of other elements or features.
- Biomedical adhesives may be given different names, including “bioadhesive”, “biological adhesive” and “surgical adhesive” among others. In this specification, such terms are used interchangeably, and all refer to compositions which are biocompatible and which result in temporary or permanent bonding of two surfaces, where at least one of the surfaces is biological and/or bonding is in a biological environment.
- The term “bulk material” is used in this specification to refer to biocompatible organic or inorganic material. This includes for example polymers from which biomedical devices are formed, prostheses, etc. The bulk material would usually be a solid phase.
- Surprisingly, it now has been found that a biomedical adhesive can be formed with broad applicability and reduced adverse biological reaction.
- The present invention therefore relates to a biomedical adhesive comprising multifunctionally activated functional groups.
- In one form of the invention, there is provided a method for bonding a bulk material to a nucleophilic or electrophilic surface including attaching a multifunctionally activated functional group to the bulk material and then contacting the functional group with the nucleophilic surface under conditions permitting covalent linkage between the surface and the functional group.
- As would be appreciated, the compound and the surface can be either electrophilic or nucleophilic, as long as each is the opposite of the other so as to enable reaction between them—such a pair of reactive groups may be called “corresponding” (eg, an activated ester and an amino group).
- The conditions are selected to be as convenient as possible. The temperature range is preferably between 0° C. and 60° C., most preferably body temperature (ie, about 37° C.). Ambient pressure is suitable. In some cases, there is also desirably sufficient surrounding fluid to facilitate or permit sufficient movement of the reactive groups (or the longer molecules to which they are attached) such that they come into close enough proximity for the covalent linkage to form.
- The invention also provides a bioadhesive attached to a bulk material for bonding the bulk material to a biological surface, the bioadhesive comprising a multifunctionally activated compound reactable with nucleophilic or electrophilic functional groups.
- The multifunctionally activated functional group is preferably an activated ester or amide.
- The invention also provides a bioadhesive covalently linking a bulk material with a biological surface, the adhesive being formed by the curing of a multifunctionally activated functional group.
- The invention also provides a biomedical device for attaching to a biological surface including a biocompatible organic or inorganic bulk material to which a multifunctionally activated compound has been bonded.
- The invention is also directed towards a method of preparing a device comprising a bulk material combined with a bioadhesive which may be stored anhydrously prior to use, comprising attaching the multifunctionally activated functional group to the bulk material and then dehydrating the device.
- The invention also provides a process for applying a bioadhesive to a surface of a biomedical device comprising the steps of
-
- providing a biomedical device comprising a biocompatible organic or inorganic bulk material
- if the surface has inadequate functional groups on its surface, applying surface functional groups to the surface, and
- covalently coupling a multifunctionally activated compound comprising at least one carboxy derivative group and at least one additional functional group that is co-reactive to the surface functional groups.
- The invention is particularly directed towards a bioadhesive for in vivo use. The invention can be used to adhere, for example, synthetic materials to which the bioadhesive multifunctionally activated compound is attached to any appropriate nucleophilic or electrophilic surface of an animal (including humans). A common nucleophilic surface to which such articles may be attached is collagen, or any other lysine-rich polypeptide (whether natural or synthetic).
- The incorporation of collagen into a device according to the invention is optional. Collagen may confer other properties on the biomedical device useful or desirable for its intended purpose. Collagen may be bonded to the biomedical device of the invention by the same surface functional groups as bind the multifunctionally activated compound or otherwise.
- The invention has particular application to biomedical devices made from a bulk material which is strongly hydrophobic. Such materials are known to be difficult to adhere in a biological environment. As detailed in a preferred embodiment, hydrophobic surfaces may first be treated by the addition of surface functional groups (such as aldehydes) by known processes (such as plasma deposition).
- Suitable multifunctionally activated functional groups include carboxy derivative groups, such as, for example, carboxylic halides, for example —COCl or —COBr; carboxylic anhydrides; lactones; carboxylic amides; or preferably carboxylic esters. A preferred group of carboxy derivative groups are esters, in particular activated esters or amides.
- The reactive groups may be selected from a class of esters, which are highly reactive towards nucleophiles. Active esters or other reactive groups derived from carboxylic acids or amides undergo elimination reactions with nucleophiles to form stable adducts as follows:
-
-
- X=halogen;
- Y=H, alkyl, or optionally active ester or reactive group;
- Nu=nucleophile (e.g. amine, thiol)
- These reactions can be applied as a curing reaction for adhesives, when di- or poly-functional reagents are used. Thus, if Z contains more than one nucleophilic group and Y contains more than one active ester or reactive group, then a cross-linked polymer results that has the properties of an adhesive. If the substrate to be glued contains nucleophilic groups (e.g. amines in collagen-coated articles or ophthalmic tissue), then direct bonding to the active ester or reactive group can occur and the formulation acts as a bioadhesive.
-
- Careful choice in the spacer component enables the synthesis of a bioadhesive that supports or inhibits cell growth, or is biodegradable or non-biodegradable. The bioadhesives can also contain other materials, such as inert biocompatible fillers, to improve the viscosity and to result in porosity after leaching.
-
- A preferred carboxy derivative group according to the invention is an activated ester group of formula (g), (e) or, in particular, of formula (h).
- Multifunctionally activated compounds are, for example, compounds of formula
R13-D-R12 (j), -
- wherein
- D is a bivalent organic radical, which may be substituted, for example, by one or more carboxy or carboxy derivative groups;
- R12 is a carboxy derivative group; and
- R13 is a further reactive group, for example a carboxy, a carboxy derivative, isocyanato, isothiocyanato or epoxy group.
- Examples of bivalent organic radicals D are, for example, an optionally branched C1-C12-alkylene; a radical of dendrimer or star bust polymer; a radical of a polyethylene glycol; a radical of a polyvinyl alcohol, for example, a polyvinyl alcohol with pendant polymerisable groups as described in WO 96/24075; or a radical of a hyperbranched polyester resin as described by M. Johansson and A. Hult in Journal of Coatings Technology, 67, No. 849, 35 (1995). D is preferably a bivalent radical of a polyethylene glycol, for example a radical of formula —CH2—CH2—(O—CH2—CH2)f—, wherein f is an integer of, for example, from 2 to 250.
- R12 is a carboxy derivative group, wherein the above given meanings and preferences apply. R13 is independently preferably a carboxy derivative group, wherein the above given meanings and preferences apply. Most preferably, R12 and R13 are identical.
- In one embodiment, the multifunctionally activated compound is polyethylene glycol that is di-substituted with succinimidyl propionate, succinimidyl succinate or succinimidyl succinimide, or the known derivatives of these functional groups.
- The method of attaching a multifunctional compound of formula (O) to a bulk material surface provided with a natural or synthetic polymer comprising co-reactive functional groups depends on the nature of the reactive groups being present in compound (j) and at the natural or synthetic polymer. The reactions are known per se, for example, from textbooks of organic chemistry.
- For example, in case that a compound of formula (j) with a carboxy, amide or ester group R13 is to be coupled to a natural or synthetic polymer containing amino, thiol or hydroxy groups, the reaction may be carried out under the conditions that are customary for ester or amide formation. It is preferred to carry out the esterification or amidation reaction in the presence of an activating agent, for example N-ethyl-N′-(3-dimethyl aminopropyl)carbodiimide (EDC), N-hydroxy succinimide (NHS) or N,N′-dicyclohexyl carbodiimide (DCC).
- In case that a compound of formula (O) with an anhydride group R13 is to be coupled to a natural or synthetic polymer containing amino, thiol or hydroxy groups the reaction may be carried out as described in organic textbooks, for example in an aprotic solvent, for example one of the above-mentioned aprotic solvents, at a temperature from room temperature to about 100° C.
- In case that a compound of formula (j) with an activated ester or amide group R13 is to be coupled to the surface of a bulk material or to a natural or synthetic polymer containing amino, thiol or hydroxy groups, the reaction may be carried out, for example, at room temperature or at elevated temperature, for example at about 20 to 100° C., in an aprotic medium.
- In case that a compound of formula (j) with an isocyanato group R13 is to be coupled to a natural or synthetic polymer containing amino or hydroxy groups, the reaction may be carried out in an inert organic solvent such as acetonitrile, an optionally halogenated hydrocarbon, for example petroleum ether, methylcyclohexane, toluene, chloroform, methylene chloride and the like, or an ether, for example diethyl ether, tetrahydrofurane, dioxane, or a more polar solvent such as DMSO, DMA, N-methylpyrrolidone or even a lower alcohol or water, at a temperature of from 0 to 100° C., preferably from 0 to 50° C. and particularly preferably at room temperature, optionally in the presence of a catalyst, for example a tertiary amine such as triethylamine or tri-n-butylamine, 1,4-diazabicyclooctane, or a tin compound such as dibutyltin dilaurate or tin dioctanoate. In addition, the reaction of the isocyanato groups with amino groups may also be carried out in an aqueous solution in the absence of a catalyst. It is advantageous to carry out the above reactions under an inert atmosphere, for example under a nitrogen or argon atmosphere.
- In case that a compound of formula (j) with an epoxy group R13 is to be coupled to a natural or synthetic polymer containing amino, thiol or hydroxy groups, the reaction may be carried out, for example, at room temperature or at elevated temperature, for example at about 20 to 100° C., in an aprotic medium using a base catalyst, for example Al(O—C1-C6-alkyl)3 or Ti(O—C1-C6-alkyl)4.
- In a preferred embodiment of the invention, the bulk material forms a biomedical device. The device may be obtainable by a process comprising the steps of
-
- providing a biomedical device comprising a biocompatible organic bulk material and having surface functional groups on its surface, and
- covalently coupling the surface functional groups with a natural or synthetic polymer comprising co-reactive groups, and
- covalently coupling a multifunctionally activated compound comprising at least one carboxy derivative group and at least one additional functional group that is co-reactive to the co-reactive groups of the natural or synthetic polymer.
- Examples of bulk materials that may be coated according to the process of the invention are natural or synthetic organic polymers, or laminates, composites or blends of said materials. Some examples of polymers are polyaddition and polycondensation polymers (polyurethanes, epoxy resins, polyethers, polyesters, polyamides, polycarbonates and polyimides); vinyl polymers (polyacrylates, polymethacrylates, polystyrene, polyethylene, polyacrylamides and halogenated derivatives thereof, polyvinyl acetate and polyacrylonitrile); elastomers (silicones, polybutadiene and polyisoprene); or modified or unmodified biopolymers (collagen, cellulose, chitosan and the like).
- Another preferred group of bulk materials are those conventionally used for the manufacture of biomedical devices, e.g. contact lenses, intraocular lenses or artificial cornea, which are not hydrophilic per se. Such materials are known to the skilled artisan and may comprise for example polysiloxanes, perfluoropolyethers (PFPE), fluorinated poly(meth)acrylates or equivalent fluorinated polymers derived e.g. from other polymerizable carboxylic acids, polyalkyl (meth)acrylates or equivalent alkylester polymers derived from other polymerizable carboxylic acids, or fluorinated polyolefines, such as fluorinated ethylene propylene, or tetrafluoroethylene, preferably in combination with specific dioxols, such as perfluoro-2,2-dimethyl-1,3-dioxol. Examples of suitable bulk materials are e.g. Lotrafilcon A, Neofocon, Pasifocon, Telefocon, Fluorsilfocon, Paflufocon, Silafocon, Elastofilcon, Fluorofocon or Teflon AF materials, such as Teflon AF 1600 or Teflon AF 2400 which are copolymers of about 63 to 73 mol % of perfluoro-2,2-dimethyl-1,3-dioxol and about 37 to 27 mol % of tetrafluoroethylene, or of about 80 to 90 mol % of perfluoro-2,2-dimethyl-1,3-dioxol and about 20 to 10 mol % of tetrafluoroethylene.
- Another preferred group of biocompatible polymers are those being conventionally used for the manufacture of biomedical devices, e.g. contact lenses, which are hydrophilic per se, since hydrophilic groups, e.g. carboxy, carbamoyl, sulfate, sulfonate, phosphate, amine, ammonium or hydroxy groups, are inherently present in the material. Such materials are known to the skilled artisan and comprise for example polyhydroxyethyl acrylate, polyhydroxyethyl methacrylate (HEMA), polyvinyl pyrrolidone (PVP), polyacrylic acid, polymethacrylic acid, polyacrylamide, poly-N,N-dimethyl acrylamide (DMA), polyvinyl alcohol, copolymers for example from two or more monomers from the group hydroxyethyl acrylate, hydroxyethyl methacrylate, N-vinyl pyrrolidone, acrylic acid, methacrylic acid, acrylamide, N,N-dimethyl acrylamide, vinyl alcohol, vinyl acetate and the like, polyalkylene glycols such as polyethylene glycols, polypropylene glycols or polyethylene/polypropylene glycol block copolymers. Typical examples are e.g. Polymacon, Tefilcon, Methafilcon, Deltafilcon, Bufilcon, Phemfilcon, Ocufilcon, Focofilcon, Etafilcon, Hefilcon, Vifilcon, Tetrafilcon, Perfilcon, Droxifilcon, Dimefilcon, Isofilcon, Mafilcon, Nelfilcon or Atlafilcon.
- An even more preferred group of bulk materials are, for example, porous polymers with improved wettability and cell growth ability as described in U.S. Pat. No. 6,015,609, WO 97/35906, WO 97/35905, WO 00/49058 or in WO 00/15686. Polymers incorporating charged units or zwitterions (such as described WO 00/15686) are also useful in this invention, and the contents of that specification are herein incorporated by reference. Additional examples are provided in European Patent Application no. 02011173.8, the contents of which are herein incorporated by reference. PFPE macromonomers and the synthesis of polymers therefrom are known e.g. from PCT applications WO 96/31546 or WO 97/35906.
- The bulk material network can, if desired, be reinforced by addition of a crosslinking agent, that is not a PFPE polymer, for example by a polyunsaturated crosslinking comonomer. Examples of typical crosslinking comonomers are allyl (meth)acrylate, lower alkylene glycol di(meth)acrylate, poly(lower alkylene) glycol di(meth)acrylate, lower alkylene di(meth)acrylate, divinyl ether, divinyl sulfone, di- and trivinylbenzene, trimethylolpropane tri(meth)acrylate, pentaerythritol tetra(meth)acrylate, bisphenol A di(meth)acrylate, methylenebis(meth)acrylamide, triallyl phthalate and diallyl phthalate. Polyunsaturated perfluoroalkyl crosslinkers of formula
Q-CH2—(CF2)q—CH2-Q (k), -
- wherein for Q the above given meanings and preferences apply, and q is an integer of, for example, from 1 to 20 and preferably from 1 to 12, are the preferred additional crosslinking comonomers. If a crosslinking comonomer is used, the amount used is in the range of from 0.01 to 40% of the expected total weight of polymer, preferably the comonomer is in the range of 0.1 to 30%, and more preferably in the range of 0.1 to 20%. Preferably the polymerization mixture does not contain a crosslinking monomer.
- The preferred bulk materials of the invention may be obtained by copolymerizing one or more PFPE macromonomers, one or more charged monomers or a suitable precursor thereof and optional further comonomers and/or additives to afford a transparent polymer in the presence of a suitable initiator. Standard methods well known in the art for effecting polymerization may be utilized, with free radical polymerization being preferred. Free radical polymerization can be simply carried out by radiating (using ultra-violet light) monomer mixtures containing a UV initiator, such as benzoin methylether, in an appropriate container or vessel. The mixture is irradiated for a sufficient time to enable polymerization between monomers to take place. Alternatively, thermal initiation using a thermal initiator such as azobisisobutyronitrile, can be employed. If a precursor of the zwitter-ionic monomer is used, the copolymer after the irradiation may be treated with a suitable reagent in order to convert the precursor units into zwitter-ionic units.
- The polymerization mixture can be converted to a polymer neat or in the presence of one or more solvents. While the structure of the components of the polymerization mixture has the most significant effect on the resulting modulus, the choice of solvent and comonomer also has an effect. Useful solvents include those selected from the following classes: esters, alcohols, ethers, and halogenated solvents. Fluorinated solvents are particularly useful and their use in combination with other solvents (in ratios varying from 1:9 to 9:1) from the classes above is especially desirable. Solvent concentrations of between 0-70% w/w, particularly 30-80% w/w, especially 55% in the polymerization mixture are desirable. Preferred solvents include acetates, particularly isopropyl acetate and tert-butyl acetate, 2-(trifluoromethyl)-2-propanol, chlorofluoroalkanes, particularly trichlorotrifluoroethane, and perfluorinated alkanes, such as perfluoro-1,3-dimethylcyclohexane, 2,2,3,3-tetrafluor-1-propanol, 2′,3′,4′,5′,6′-pentafluoroacetophenone, 1,1,1-trifluoro-3,4-pentadione, 2′,3′,4′,5′,6′-pentafluorobenzyl alcohol and the like. A particular preferred solvent is water or an aqueous solution comprising, for example, one or more organic solvents, for example a C1-C4-alkanol such as methanol or ethanol, or a fluorinated alkane. Water may be 1 to 70% w/w, preferably 2 to 50% w/w and particularly preferably 3 to 30% w/w, in each case based on the entire formulation.
- The bulk materials may form porous substrates. Porosity may be provided by the inherent porosity of the material. Alternatively, pores may be introduced into the polymers by various procedures such as those disclosed in PCT applications WO 00/15686. In case of porous bulk materials, a polar solvent, for example water, a C1-C4-alkanol, and/or a surfactant, preferably a fluorinated surfactant, may be incorporated into the polymerization mixture. The use of surfactants is an effective means of controlling the size and density of the pores. Non-ionic surfactants containing fluorine are preferred. Particularly preferred surfactants include commercially available fluorinated surfactants such as Zonyl (DuPont) and Fluorad (3M). Zonyl surfactants, which are made of a perfluorinated hydrophobic tail and hydrophilic poly(ethylene oxide) head group, are a particularly preferred surfactant for use in the process of the present invention.
- Suitable bulk materials are those obtainable by copolymerizing one or more macromonomers comprising at least one PFPE unit, wherein the above-given meanings and preferences apply, and at least one zwitter-ionic monomer or a precursor thereof, wherein again the above-given meanings and preferences apply, in an aqueous solution and, if a zwitter-ionic monomer precursor has been used, converting the precursor units into charged units after the copolymerization reaction. A particular preferred reaction medium in this context is an aqueous solution comprising a C1-C4-alkanol, in particular methanol or ethanol, a fluorinated surfactant and optionally a fluorinated alkane.
- The surface of the bulk material may inherently contain functional groups or may be provided with covalently attached functional groups, for example, by plasma deposition, particularly if it is hydrophobic. The method of coating a surface by plasma deposition is known to the skilled artisan and is described in, e.g. WO 98/52620 and WO 00/29548. Typical examples of reactive groups being introduced to the surface of the bulk material by plasma surface preparation include aldehyde groups, amino groups, hydroxy groups, carboxy groups, carbonyl groups, sulfonic acid groups, sulfonyl chloride groups and groups able to be replaced by amino or hydroxy groups, such as halo groups. Aldehyde groups, thiol groups, amino groups, hydroxy groups and carboxy groups are preferred.
- Examples of the natural or synthetic polymer used are cell-adhesive glycoproteins like collagens (various types), fibronectin, vitronectin, laminin, poly(ethyl imine), amino dextran, PAMAM dendrimers, poly(allyl amine), poly(vinyl alcohol), poly(arylic acid) and poly(methacrylic acid). Collagen and collagen-like proteins are preferred. The coupling of cell-adhesive glycoproteins to plasma polymers covalently bound to the underlying bulk material is known and described, for example, in WO 00/29548.
- Moreover, biomedical devices according to the invention comprising a preferred bulk material, that is a bulk material obtainable by copolymerizing a macromonomer comprising at least one PFPE unit and a zwitter-ionic monomer in an aqueous solution, offer the additional advantage, that unlike other hydrophobic materials, for example those disclosed in WO 00/15686, they may be hydrated very easily. Accordingly, the biomedical devices of the invention may be dehydrated after their preparation and stored for extended periods without loss of adhesive activity. Such a biomedical device, for example an onlay, is then immediately ready for use, by just placing it in water for a short period, typically for about 1 to 10 minutes and particularly for about 2 minutes, which is sufficient to re-hydrate both the bulk material and the coating (so as to re-activate the hydrolytically unstable functional groups of the multifunctionally activated compound). All of these advantages naturally apply not only to contact lenses but also to other biomedical mouldings according to the invention as mentioned before.
- In a further preferred form of the invention, biomedical devices (such as corneal inlays and onlays or lenticules) are formed from a polymer as described above, and then dried and stored in anhydrous conditions. This maintains the multifunctionally activated compounds' unreacted reactive groups such that they can bond to tissue upon implantation or affixation of the device to tissue, after re-hydration to increase polymer chain mobility.
- The biomedical devices of the present invention such as in particular corneal onlays and inlays may be fixed on the cornea by just placing the device in intimate contact with the corneal tissue for a certain time period, for example for about 5 to 30 minutes and especially for 10 to 20 minutes. Such onlays and inlays are easier to handle, since the use thereof does not involve, for example, a premixing of glue components or time pressure upon the surgeon due to specific curing times of the glue components. In addition, no tedious removal of excess glue after fixing onto the cornea is necessary, and the previous problem of inhibition of overgrowth by glue residues does not exist.
- Preferably, the cornea is previously prepared for the attachment of an onlay, for example, by removing the epithelial cell layers of the cornea by scraping and/or washing the eye, for example, with ethanol/water mixtures. Ideally the cornea surface and the lenticule are dried with surgical sponges or the like. It is desirable to minimise the fluid and air between the lenticule and the cornea surface. Excess fluid and air may be removed by applying pressure across the membrane using a rolling action with a surgical instrument. Such onlays provide a new route towards implanting a corneal onlay onto a cornea which is easy to perform, does not affect the wearers vision, and is safe. In particular, a mechanically stable fixation of the implant on the cornea is obtained which lasts for a period of time sufficient for normal biological function to recover after surgery. This may include the chance to allow the epithelial cells to recover, grow over the implant and thus fix it in a persistent manner.
- The invention is particularly suitable for corneal inlays where cell growth ability is less important. Cell growth ability may be impeded by higher charged unit content, such as over 10% w/w, although this may be overcome by surface modification of the inlay (eg collagen attachment). The inlay may be implanted using known techniques. For example, an incision may be made in the stroma, into which the re-hydrated inlay is placed. The inlay then attaches to the stroma through reaction of the re-activated functional groups of the multifunctionally activated compound with no additional material being required. Polymers with charged unit content of around 20% are useful for this application.
- The present invention is further described by the following non-limiting examples. If not specified otherwise, all parts are by weight. Temperatures are in degree Celsius.
- The following formulation was prepared in a glass vial furnished with a stirrer. The components were added in order of decreasing hydrophilicity and mixed well, prior to the addition of the photoinitiator. After the addition of the photoinitiator (Darocur 1173), the mixing was continued for a further five minutes. The resulting solution was then placed in polypropylene moulds and polymerised for 3 hours under the irradiation of broad spectrum UV lamps. (1 mW/cm−2). The polymers (20 mm diameter disc 50 to 250 microns thick) were removed from the mold and placed through a general extraction procedure to remove any unpolymerised components. This procedure consists of a 2×24 h soaking in a fluorinated solvent such as Vertrel XF (DuPont), TCTFE (Aldrich) or HFE 7100 (3M), then 2×24 hr immersion in isopropyl acetate and subsequent immersion for 2×24 h in methanol. The polymers were then hydrated by a graded solvent change from methanol to ethanol (2×24 hr), 75% ethanol/water (2×24 hr), 50% ethanol/water (2×24 hr), 25% ethanol/water (2×24 hr), then pure water or saline (2×24 hr). This assists in extracting unpolymerised monomers/solvents/surfactants.
- Examples 1 to 4 used a combination of Part A and Part B for polymerisation as follows:
- Part A consisted of (parts by weight):
PFPE macromonomer #1 4.5 PFPE macromonomer #2 0.5 Ethanol 2.5 PFDMCH 3.0 - Part B consisted of a 50% (w/w) solution of [2-(methacryloyloxy)ethyl]dimethyl(3-sulfopropyl)-ammonium inner salt (zwitterion) in water.
Component Amount Part A 1.749 Part B 0.143 Surfactant Zonyl FSK 0.1841 Darocur 1173 0.0024 EWC (%) 27.5 Optical Clarity 95.6 (%) Porosity (A280) 0.815 - Explanation of Abbreviations:
-
- PFPE macromonomer #1: perfluorinated macromer obtained by endcapping a perfluoropolyether diol (Ausimont, Italy, Mw=2000) with isocyanatoethyl methacrylate as described in Chaouk H. et al., J. Appl. Polym. Sci., 2001, 80, 1756;
- PFPE macromonomer #2: perfluorinated macromer obtained by endcapping a perfluoropolyether diol (Ausimont, Italy, Mw=1000) with isocyanatoethyl methacrylate as described in Chaouk H. et al., J. Appl. Polym. Sci., 2001, 80, 1756;
- Zonyl FSK, FSA, FSO100 and FSN100=non-ionic fluorinated surfactants (DuPont);
- Darocur®1173=photoinitiator (Ciba Speciality Chemicals).
- PFDMCH=perfluorodimethylcyclohexane
- Equilibrium water contents (EWC) (expressed as percentages) and porosity measurements are measured as reported by Chaouk H. et al, J. Appl. Polym. Sci., 2001, 80, 1756.
- Optical haze (%) is measured using a Gardner PG-5500 digital photometric unit. Optical clarity is calculated by subtracting optical haze from 100%.
- The formulation of Example 1 was covalently coated, both sides, with type 1 collagen according to the procedure disclosed in WO 00/29548. The collagen coated materials were then exchanged from phosphate buffered saline (PBS) to MilliQ water, then 100% ethanol and finally acetonitrile. The acetonitrile was then replaced by dry acetonitrile. 250 μl of poly(ethylene glycol) di(succinimidyl propionate) solution (582 mg, Shearwater Polymers, dissolved in 1.2 ml of dry acetonitrile) were added to each of the acetonitrile equilibrated collagen coated self-hydrating polymer samples in separate vials. After 20 minutes of incubation, 3 samples (samples 1,2,3) were evaporated to dryness using a rotary evaporator. Another 3 samples (4,5,6) had the excess crosslinker solution removed with a pipette. Dry acetonitrile (2 ml) was added to these vials and they were gently shaken before removing excess acetonitrile solution with a pipette. The three samples (samples 4,5,6) were then evaporated to dryness using a rotary evaporator. All samples were stored under vacuum over P2O5 until used, in this case seven days later, although lenticules made in this manner could be stored much longer.
- The dried surface-modified lenticules of Example 45 are hydrated by placing them in water. The use of hot water sped up the hydration process. The hydration process may be performed using PBS instead of water or aqueous mixtures. Once hydrated, the lenticules were surface dried using lint-free tissue paper and then placed on a freshly debrided bovine cornea. Excess fluid and bubbles were expelled from under the lenticule by gently wiping across the anterior surface of the lenticule. The lenticule was allowed to cure for 15 to 19 minutes before the adhesion was assessed using a vacuum tester (a detachment threshold>5.5 means that the adhesion is greater than what was able to be tested using the vacuum tester):
hydration time cure time detachment Sample (minutes) (minutes) threshold 1 2 16 >5.5 2 2 15 >5.5 3 2 15 >5.5 4 2 15 >5.5 5 2 17 3.5 6 2 19 >5.5 - Poly(ethylene glycol) di(succinimidyl propionate) (50 mg, Shearwater Polymers) was dissolved in water for irrigation (125 μl, Baxter products) within 30 seconds by vigorous mixing. A hydrated but surface dried double sided collagen coated perfluoropolyether lenticule was cast in a contact lens mould. The concave cup of the lenticule was filled with poly(ethylene glycol) di(succinimidyl propionate) solution. After two minutes the solution was removed by pipettor and the excess poly(ethylene glycol) di(succinimidyl propionate) solution was removed by washing the modified lenticule for 4 minutes in water (for irrigation, 25 ml, Baxter products). The lenticules were then surface dried using lint free tissue paper. The modified lenticules were then placed on a freshly debrided feline cornea. Excess fluid and bubbles were expelled from under the lenticule by gently wiping across the face of the lenticule. The lenticules were allowed to cure for 10 minutes before antibacterial cream is applied to the eyes and the cat is allowed to gain consciousness. Six lenticules adhered to feline cornea for between 14 and 90 days. In one case, the epithelium completely covered the lenticule by day 12 post-implantation. The lenticule remained adhered to the cornea and fully epithelized beyond day 90. After adhesive failure the wound beds re-epithelized within a normal time period indicating the adhesive did not induce permanent damage to the cornea.
- It will be understood that the invention disclosed and defined herein extends to all alternative combinations of two or more of the individual features mentioned or evidence from the text or drawings. All of these different combinations constitute various alternative aspects of the invention.
Claims (35)
1. A method for bonding an inorganic or organic bulk material to a nucleophilic or electrophilic surface including:
attaching a multifunctionally activated compound to the bulk material, the compound selected to be electrophilic or nucleophilic opposite to the surface;
then contacting the multifunctionally activated compound with the surface under conditions permitting covalent linkage between the surface and the multifunctionally activated compound.
2. A method according to claim 1 in which the bulk material combined with the multifunctionally activated compound is dehydrated before contacting the surface.
3. A method according to claim 1 in which the multifunctionally activated compound includes an activated ester or amide.
4. A method according to claim 3 , wherein the multifunctionally activated compound is of formula
R13-D-R12
wherein
D is a bivalent organic radical, which is unsubstituted or substituted by one or more carboxy or carboxy derivative groups;
R12 is a carboxy derivative group; and
R13 is a further reactive group selected from the group consisting of a carboxy, carboxy derivative, isocyanato, isothiocyanato and epoxy group.
5. A method according to claim 4 , wherein D is an optionally branched C1-C12-alkylene; a radical of a dendrimer or star-bust polymer; a radical of a polyethylene glycol; a radical of a polyvinyl alcohol; or a radical of a hyperbranched polyester resin, preferably the radical of a polyethylene glycol.
6. A method according to claim 4 , wherein R12 and R13 are each an activated ester group.
7. A method according to claim 1 wherein the multifunctionally activated compound is polyethylene glycol that is di-substituted with succinimidyl propionate, succinimidyl succinate or succinimidyl succinamide, and is first reacted with nucleophilic groups on the surface of the bulk material.
10. A method according to claim 1 in which the bulk material combined with the multifunctionally activated compound is washed to remove excess multifunctionally activated compound before contacting the surface.
11. A method according to claim 1 in which a natural or synthetic polymer is comprising co-reactive groups is first bonded to the bulk material.
12. A method according to claim 11 in which the natural or synthetic polymer is selected from the group consisting of cell-adhesive glycoproteins like collagens (various types), fibronectin, vitronectin, laminin, poly(ethyl imine), amino dextran, PAMAM dendrimers, poly(allyl amine), poly(vinyl alcohol), poly(arylic acid) and poly(methacrylic acid).
13. A method according to claim 10 in which the natural or synthetic polymer is collagen.
14. A bioadhesive material attached to a bulk material for bonding the bulk material to a biological surface, the bioadhesive comprising a multifunctionally activated compound reactable with nucleophilic or electrophilic functional groups of the surface.
15. A bioadhesive according to claim 14 in which the multifunctionally activated compound is bound to a natural or synthetic polymer bound to the bulk material.
16. A bioadhesive according to claim 15 in which the multifunctionally activated compound is of formula
R13-D-R12 (j)
wherein
D is a bivalent organic radical, which is unsubstituted or substituted by one or more carboxy or carboxy derivative groups;
R12 is a carboxy derivative group; and
R13 is a further reactive group selected from the group consisting of a carboxy, carboxy derivative, isocyanato, isothiocyanato and epoxy group.
17. A biomedical device for attaching to a biological surface by a bioadhesive including a biocompatible organic or inorganic bulk material to which a multifunctionally activated compound has been bound, the bound multifunctionally actived compound being capable of being stored anhydrously.
18. A biomedical device according to claim 17 in which the multifunctionally activated compound is of formula
R13-D-R12 (j)
wherein
D is a bivalent organic radical, which is unsubstituted or substituted by one or more carboxy or carboxy derivative groups;
R12 is a carboxy derivative group; and
R13 is a further reactive group selected from the group consisting of a carboxy, carboxy derivative, isocyanato, isothiocyanato and epoxy group, one or more of the groups being hydralytically unstable.
19. A biomedical device according to claim 18 further comprising a natural or synthetic polymer having co-reactive groups.
20. A biomedical device according to claim 18 , wherein D is an optionally branched C1-C12-alkylene; a radical of a dendrimer or star bust polymer; a radical of a polyethylene glycol; a radical of a polyvinyl alcohol; or a radical of a hyperbranched polyester resin, preferably the radical of a polyethylene glycol.
21. A biomedical device according to claim 18 , wherein R12 and R13 are each an activated ester group.
22. A biomedical device according to claim 17 wherein the multifunctionally activated compound is polyethylene glycol that is di-substituted with succinimidyl propionate, succinimidyl succinate or succinimidyl succinamide, and is first reacted with nucleophilic groups on the surface of the bulk material.
25. A biomedical device according to any one of claims 17 further comprising a natural or synthetic polymer.
26. A biomedical device according to claim 17 stored anhydrously prior to use wherein one or more of the groups of the multifunctionally activated compound are unreacted.
27. A biomedical device according to claim 23 , stored anhydrously prior to use wherein one or more of the groups of the multifunctionally activated compound are unreacted.
28. A biomedical device according to claim 17 , the device being an opthalmic device, a contact lens, a corneal onlay, a corneal inlay, a lenticule or an intraocular lens.
29. A process for applying a bioadhesive to a surface of a biomedical device comprising a biocompatible organic or inorganic bulk material including the steps of
if the surface is not nucleophilic or electrophilic, applying nucleophilic or electrophilic functional groups to the surface,
covalently bonding to the surface a multifunctionally activated compound, the compound selected to be electrophilic or nucleophilic opposite to the fuctional groups,
washing the surface of unbound multifunctionally activated compound.
30. A process for applying a bioadhesive to a surface of a biomedical device comprising a biocompatible organic or inorganic bulk material including the steps of
if the surface is not nucleophilic or electrophilic, applying nucleophilic or electrophilic functional groups to the surface,
covalently bonding the functional groups to a natural or synthetic polymer comprising co-reactive groups,
covalently coupling to the natural or synthetic polymer a multifunctionally activated compound, the compound selected to be electrophilic or nucleophilic opposite to the co-reactive groups,
washing the natural or synthetic polymer of unbound multifunctionally activated compound.
31. A process according to claim 29 , wherein the multifunctional compound is of formula
R13-D-R12 (j)
wherein
D is a bivalent organic radical, which is unsubstituted or substituted by one or more carboxy or carboxy derivative groups;
R12 is a carboxy derivative group: and
R13 is a further reactive group selected from the group consisting of a carboxy, carboxy derivative, isocyanato, isothiocyanato and epoxy group.
32. A process according to claim 29 , wherein the biocompatible organic or inorganic bulk material is a PFPE polymer.
33. A process according to claim 30 , wherein the biocompatible organic or inorganic bulk material is a PFPE Polymer.
34. The use of a biomedical device according to claim 17 as an intraocular lens for the implantation into or onto the cornea.
35. The use of a biomedical device according to claim 23 as an intraocular lens for the implantation into or onto the cornea.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02011173A EP1364663A1 (en) | 2002-05-21 | 2002-05-21 | Ocular devices with functionalized surface with adhesive properties |
EP02011173.8 | 2002-05-21 | ||
PCT/AU2003/000612 WO2003097759A1 (en) | 2002-05-21 | 2003-05-21 | Biomedical adhesive |
Publications (1)
Publication Number | Publication Date |
---|---|
US20050238692A1 true US20050238692A1 (en) | 2005-10-27 |
Family
ID=29286127
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/515,164 Abandoned US20050238692A1 (en) | 2002-05-21 | 2003-05-21 | Biomedical adhesive |
US10/515,218 Expired - Fee Related US7479530B2 (en) | 2002-05-21 | 2003-05-21 | Polymer having charged units |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/515,218 Expired - Fee Related US7479530B2 (en) | 2002-05-21 | 2003-05-21 | Polymer having charged units |
Country Status (7)
Country | Link |
---|---|
US (2) | US20050238692A1 (en) |
EP (3) | EP1364663A1 (en) |
JP (2) | JP4934279B2 (en) |
CN (2) | CN1313557C (en) |
AU (2) | AU2003225338B2 (en) |
CA (2) | CA2487041C (en) |
WO (2) | WO2003097711A1 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110208300A1 (en) * | 2008-04-04 | 2011-08-25 | ForSight Labs. LLC | Corneal Onlay Devices and Methods |
US20110307057A1 (en) * | 2006-04-28 | 2011-12-15 | Leonard Pinchuk | Polymer Adhesive for an Intraocular Lens that Minimizes Posterior Capsule Opacification |
US8409606B2 (en) | 2009-02-12 | 2013-04-02 | Incept, Llc | Drug delivery through hydrogel plugs |
US8802072B2 (en) | 2011-04-13 | 2014-08-12 | Massachusetts Institute Of Technology | Biocompatible adhesive materials and methods |
US10226417B2 (en) | 2011-09-16 | 2019-03-12 | Peter Jarrett | Drug delivery systems and applications |
US10555804B2 (en) | 2008-04-04 | 2020-02-11 | Journey1, Inc. | Therapeutic device for pain management and vision |
US10596038B2 (en) | 2009-10-23 | 2020-03-24 | Journey1, Inc. | Corneal denervation for treatment of ocular pain |
US10627649B2 (en) | 2009-10-23 | 2020-04-21 | Journey1, Inc. | Conformable therapeutic shield for vision and pain |
WO2019222377A3 (en) * | 2018-05-15 | 2020-07-23 | Biodevek, Inc. | Biocompatible adhesive materials with ionic and covalent interaction |
US11126011B2 (en) | 2011-04-28 | 2021-09-21 | Journey1, Inc. | Contact lenses for refractive correction |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPQ197899A0 (en) * | 1999-08-02 | 1999-08-26 | Commonwealth Scientific And Industrial Research Organisation | Biomedical compositions |
EP1364663A1 (en) * | 2002-05-21 | 2003-11-26 | Commonwealth Scientific And Industrial Research Organisation | Ocular devices with functionalized surface with adhesive properties |
AU2002950469A0 (en) * | 2002-07-30 | 2002-09-12 | Commonwealth Scientific And Industrial Research Organisation | Improved biomedical compositions |
US20050142315A1 (en) * | 2003-12-24 | 2005-06-30 | Desimone Joseph M. | Liquid perfluoropolymers and medical applications incorporating same |
US20050271794A1 (en) * | 2003-12-24 | 2005-12-08 | Synecor, Llc | Liquid perfluoropolymers and medical and cosmetic applications incorporating same |
NZ550964A (en) * | 2004-04-28 | 2011-05-27 | Angiodevice Internat Gmbh | Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use |
JP4975627B2 (en) | 2004-10-07 | 2012-07-11 | アクタマックス サージカル マテリアルズ リミテッド ライアビリティ カンパニー | Polysaccharide-based polymeric tissue adhesives for medical applications |
US7201918B2 (en) * | 2004-11-16 | 2007-04-10 | Microvention, Inc. | Compositions, systems and methods for treatment of defects in blood vessels |
WO2006067638A2 (en) * | 2004-12-20 | 2006-06-29 | Amo Groningen B.V. | Amphiphilic block copolymers and their use |
SE0403092D0 (en) | 2004-12-20 | 2004-12-20 | Amo Groningen Bv | Amphiphilic block copolymers and their use |
US8795367B2 (en) * | 2005-06-03 | 2014-08-05 | Arthrodisc, L.L.C. | Minimally invasive apparatus to manipulate and revitalize spinal column disc |
US7608710B2 (en) * | 2005-06-07 | 2009-10-27 | Omnova Solutions Inc. | Cationic surfactants |
US20070116741A1 (en) * | 2005-11-21 | 2007-05-24 | Bausch & Lomb Incorporated | Contact lenses with mucin affinity |
US7559949B2 (en) * | 2006-04-28 | 2009-07-14 | Leonard Pinchuk | Injectable intraocular lens that minimizes posterior capsule opacification and methods and materials for realizing same |
WO2007128051A1 (en) * | 2006-05-03 | 2007-11-15 | Vision Crc Limited | Biological polysiloxanes |
AU2007247850B2 (en) | 2006-05-03 | 2013-05-02 | Vision Crc Limited | Eye treatment |
CN100435858C (en) * | 2006-10-23 | 2008-11-26 | 厦门大学 | The composite skeletal agglutinant made by sodium alginate-carboxyl methyl cellulose and its preparation method |
CN100500227C (en) * | 2006-10-23 | 2009-06-17 | 厦门大学 | Skeletal agglutinant conglutinating method |
JP5539725B2 (en) | 2006-11-27 | 2014-07-02 | アクタマックス サージカル マテリアルズ リミテッド ライアビリティ カンパニー | Branched end reactants and polymer hydrogel tissue adhesives produced therefrom |
WO2009064963A2 (en) | 2007-11-14 | 2009-05-22 | E. I. Du Pont De Nemours And Company | Oxidized cationic polysaccharide-based polymer tissue adhesive for medical use |
JP2009168875A (en) * | 2008-01-11 | 2009-07-30 | Mo-Wei Hung | Forming method for silicon contact lens and its structure |
EP2296580A2 (en) * | 2008-04-04 | 2011-03-23 | Forsight Labs, Llc | Corneal onlay devices and methods |
US8551136B2 (en) | 2008-07-17 | 2013-10-08 | Actamax Surgical Materials, Llc | High swell, long-lived hydrogel sealant |
US8466327B2 (en) | 2008-11-19 | 2013-06-18 | Actamax Surgical Materials, Llc | Aldehyde-functionalized polyethers and method of making same |
EP2349357B1 (en) | 2008-11-19 | 2012-10-03 | Actamax Surgical Materials LLC | Hydrogel tissue adhesive formed from aminated polysaccharide and aldehyde-functionalized multi-arm polyether |
EP2199855B1 (en) * | 2008-12-19 | 2016-07-20 | Obducat | Methods and processes for modifying polymer material surface interactions |
US8109997B2 (en) | 2009-01-18 | 2012-02-07 | Eyeon Medical Ltd. | Hydrophobic pseudo-endothelial implants for treating corneal edema |
EP2416811B1 (en) | 2009-04-09 | 2015-09-09 | Actamax Surgical Materials LLC | Hydrogel tissue adhesive having reduced degradation time |
WO2011002956A1 (en) | 2009-07-02 | 2011-01-06 | E. I. Du Pont De Nemours And Company | Aldehyde-functionalized polysaccharides |
US8580950B2 (en) | 2009-07-02 | 2013-11-12 | Actamax Surgical Materials, Llc | Aldehyde-functionalized polysaccharides |
WO2011035044A1 (en) * | 2009-09-16 | 2011-03-24 | University Of Kansas | Fluorinated polymers and associated methods |
US8591025B1 (en) | 2012-09-11 | 2013-11-26 | Nexisvision, Inc. | Eye covering and refractive correction methods for LASIK and other applications |
CN103281995B (en) | 2010-10-25 | 2016-04-06 | 内希斯视觉股份有限公司 | Identify the method and apparatus for the eyes covering of vision |
CN102086249B (en) * | 2010-12-27 | 2012-07-04 | 浙江大学 | Method for preparing hyperbranched ethylene or acrylamide polymer by inverse emulsion polymerization |
US9358122B2 (en) | 2011-01-07 | 2016-06-07 | K2M, Inc. | Interbody spacer |
JP2014514613A (en) | 2011-04-28 | 2014-06-19 | ネクシスビジョン, インコーポレイテッド | Ocular covering and refractive correction methods and devices with improved tear flow, comfort and / or applicability |
WO2013011511A1 (en) | 2011-07-18 | 2013-01-24 | Mor Research Applications Ltd. | A device for adjusting the intraocular pressure |
WO2013049527A1 (en) * | 2011-09-30 | 2013-04-04 | 3M Innovative Properties Company | A conformable coating and composition |
US9465233B2 (en) | 2012-04-20 | 2016-10-11 | Nexisvision, Inc. | Bimodular contact lenses |
WO2013184239A1 (en) | 2012-04-20 | 2013-12-12 | Nexisvision, Inc. | Contact lenses for refractive correction |
US8859705B2 (en) | 2012-11-19 | 2014-10-14 | Actamax Surgical Materials Llc | Hydrogel tissue adhesive having decreased gelation time and decreased degradation time |
US9486311B2 (en) | 2013-02-14 | 2016-11-08 | Shifamed Holdings, Llc | Hydrophilic AIOL with bonding |
US10195018B2 (en) | 2013-03-21 | 2019-02-05 | Shifamed Holdings, Llc | Accommodating intraocular lens |
CA2907441C (en) | 2013-03-21 | 2023-05-23 | Shifamed Holdings, Llc | Accommodating intraocular lens |
US20160184474A1 (en) | 2013-07-29 | 2016-06-30 | Actamax Surgical Materials, Llc | Low swell tissue adhesive and sealant formulations |
US9341864B2 (en) | 2013-11-15 | 2016-05-17 | Nexisvision, Inc. | Contact lenses having a reinforcing scaffold |
WO2015116559A1 (en) | 2014-01-29 | 2015-08-06 | Nexisvision, Inc. | Multifocal bimodulus contact lenses |
AU2015306613B2 (en) | 2014-08-26 | 2018-01-25 | Shifamed Holdings, Llc | Accommodating intraocular lens |
CN107001614B (en) * | 2014-11-19 | 2020-01-21 | 索尔维特殊聚合物意大利有限公司 | Zwitterionic derivatives of (per) fluoropolyethers |
HUE042067T2 (en) | 2015-02-02 | 2019-06-28 | Coloplast As | Ostomy device |
PL3280368T3 (en) | 2015-04-10 | 2019-11-29 | Coloplast As | Ostomy device |
US10220118B2 (en) * | 2015-10-26 | 2019-03-05 | Syracuse University | Self-replenishing boundary lubrication in hydrogels using zwitterionic polymers |
US11141263B2 (en) | 2015-11-18 | 2021-10-12 | Shifamed Holdings, Llc | Multi-piece accommodating intraocular lens |
US10350056B2 (en) | 2016-12-23 | 2019-07-16 | Shifamed Holdings, Llc | Multi-piece accommodating intraocular lenses and methods for making and using same |
CA3064855A1 (en) | 2017-05-30 | 2018-12-06 | Shifamed Holdings, Llc | Surface treatments for accommodating intraocular lenses and associated methods and devices |
CA3066081A1 (en) | 2017-06-07 | 2018-12-13 | Shifamed Holdings, Llc | Adjustable optical power intraocular lenses |
JP2019006891A (en) * | 2017-06-23 | 2019-01-17 | トーヨーポリマー株式会社 | Antifogging coating composition and antifogging transparent sheet using the same |
JP6782365B2 (en) * | 2017-08-30 | 2020-11-11 | 富士フイルム株式会社 | Adhesives for endoscopes, cured products, endoscopes and methods for manufacturing endoscopes |
DE102020124372A1 (en) | 2020-09-18 | 2022-03-24 | Carl Zeiss Meditec Ag | Tissue adhesive for use in a treatment procedure in which an ophthalmic implant is implanted in a human or animal patient, and ophthalmic implantation system |
WO2022126134A1 (en) * | 2020-12-11 | 2022-06-16 | W. L. Gore & Associates, Inc. | Apparatuses, methods and systems that include a synthetic material for ophthalmic surgeries |
CN115584293B (en) * | 2021-07-06 | 2023-09-15 | 中国石油化工股份有限公司 | Lubricating oil friction improver and preparation method and application thereof |
CN113929910B (en) * | 2021-12-07 | 2023-02-07 | 郑州大学 | Hyperbranched polymer underwater adhesive based on polyfunctional group rigid hydrophobic component and preparation method and application thereof |
Citations (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3185660A (en) * | 1962-08-15 | 1965-05-25 | Du Pont | Stable polymeric dispersions |
US4091165A (en) * | 1971-07-01 | 1978-05-23 | Mitsubishi Petrochemical Co., Ltd. | Surface processing copolymer for synthetic papers |
US4619965A (en) * | 1984-07-19 | 1986-10-28 | Nippon Paint Co., Ltd. | Dispersion stabilizer and its use |
US5122614A (en) * | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
US5162430A (en) * | 1988-11-21 | 1992-11-10 | Collagen Corporation | Collagen-polymer conjugates |
US5264214A (en) * | 1988-11-21 | 1993-11-23 | Collagen Corporation | Composition for bone repair |
US5304595A (en) * | 1988-11-21 | 1994-04-19 | Collagen Corporation | Collagen-polymer conjugates |
US5306500A (en) * | 1988-11-21 | 1994-04-26 | Collagen Corporation | Method of augmenting tissue with collagen-polymer conjugates |
US5354336A (en) * | 1991-01-29 | 1994-10-11 | Autogenesis Technologies, Inc. | Method for bonding soft tissue with collagen-based adhesives and sealants |
US5470911A (en) * | 1988-11-21 | 1995-11-28 | Collagen Corporation | Glycosaminoglycan-synthetic polymer conjugates |
US5475052A (en) * | 1988-11-21 | 1995-12-12 | Collagen Corporation | Collagen-synthetic polymer matrices prepared using a multiple step reaction |
US5527856A (en) * | 1988-11-21 | 1996-06-18 | Collagen Corporation | Method of preparing crosslinked biomaterial compositions for use in tissue augmentation |
US5550187A (en) * | 1988-11-21 | 1996-08-27 | Collagen Corporation | Method of preparing crosslinked biomaterial compositions for use in tissue augmentation |
US5565519A (en) * | 1988-11-21 | 1996-10-15 | Collagen Corporation | Clear, chemically modified collagen-synthetic polymer conjugates for ophthalmic applications |
US5573934A (en) * | 1992-04-20 | 1996-11-12 | Board Of Regents, The University Of Texas System | Gels for encapsulation of biological materials |
US5583114A (en) * | 1994-07-27 | 1996-12-10 | Minnesota Mining And Manufacturing Company | Adhesive sealant composition |
US5614587A (en) * | 1988-11-21 | 1997-03-25 | Collagen Corporation | Collagen-based bioadhesive compositions |
US5643464A (en) * | 1988-11-21 | 1997-07-01 | Collagen Corporation | Process for preparing a sterile, dry crosslinking agent |
US5744545A (en) * | 1988-11-21 | 1998-04-28 | Collagen Corporation | Biocompatible adhesive compositions |
US5800541A (en) * | 1988-11-21 | 1998-09-01 | Collagen Corporation | Collagen-synthetic polymer matrices prepared using a multiple step reaction |
US5874500A (en) * | 1995-12-18 | 1999-02-23 | Cohesion Technologies, Inc. | Crosslinked polymer compositions and methods for their use |
US5994133A (en) * | 1995-04-04 | 1999-11-30 | Novartis Ag | Cell growth substrate polymer |
US6225367B1 (en) * | 1998-09-15 | 2001-05-01 | Novartis Ag | Polymers |
US6232430B1 (en) * | 1996-10-23 | 2001-05-15 | Jds Uniphase Photonics C.V. | Cross-linkers for cross-linkable optical polycarbonates |
US6326025B1 (en) * | 1998-12-30 | 2001-12-04 | Depuy Orthopaedics, Inc | Tissue reactive adhesive compositions |
US20020042473A1 (en) * | 1995-12-18 | 2002-04-11 | Trollsas Olof Mikael | Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use |
US20020049495A1 (en) * | 2000-03-15 | 2002-04-25 | Kutryk Michael John Bradley | Medical device with coating that promotes endothelial cell adherence |
US6428576B1 (en) * | 1999-04-16 | 2002-08-06 | Endospine, Ltd. | System for repairing inter-vertebral discs |
US6780942B2 (en) * | 2001-12-20 | 2004-08-24 | Eastman Kodak Company | Method of preparation of porous polyester particles |
US6844028B2 (en) * | 2001-06-26 | 2005-01-18 | Accelr8 Technology Corporation | Functional surface coating |
US6864350B2 (en) * | 1996-09-26 | 2005-03-08 | Nektar Therapeutics Al, Corporation | Soluble, degradable poly (ethylene glycol) derivatives for controllable release of bound molecules into solution |
US20060160957A1 (en) * | 2000-03-24 | 2006-07-20 | Beat Muller | Novel Polymers |
US20070299227A1 (en) * | 1999-07-05 | 2007-12-27 | Achim Gopferich | Biodegradable block copolymers with modifiable surface |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPN215995A0 (en) | 1995-04-04 | 1995-04-27 | Ciba-Geigy Ag | Novel materials |
GB2303632B (en) * | 1995-07-24 | 1999-03-10 | Toagosei Co Limited | Curable emulsion and coating material comprising the same |
KR20000004952A (en) | 1996-03-27 | 2000-01-25 | 더블류. 하링, 지. 보이롤 | Producing method of porous polymer from mixture |
NZ331734A (en) | 1996-03-27 | 2000-01-28 | Novartis Ag | Process for manufacture of a porous polymer comprising dispersing a porogen in a monomer phase where the monomer has at least one perfluoropolyether unit and the porogen is a substituted polyalkleneglycol |
CA2248045C (en) | 1996-04-04 | 2006-11-07 | Novartis Ag | High water content porous polymer |
AU8017498A (en) * | 1997-05-16 | 1998-12-11 | Commonwealth Scientific And Industrial Research Organisation | Collagen-like polymers with cell binding activity |
WO1999017120A1 (en) * | 1997-09-26 | 1999-04-08 | Becton, Dickinson And Company | Preparing conjugates using polyethylene glycol linkers |
JP4573376B2 (en) * | 1998-09-21 | 2010-11-04 | 株式会社メニコン | Ophthalmic lens material and manufacturing method thereof |
AR021240A1 (en) * | 1998-11-13 | 2002-07-03 | Commw Scient Ind Res Org | COUPLED PEPTIDES |
WO2000051538A1 (en) * | 1999-03-01 | 2000-09-08 | Uab Research Foundation | Porous tissue scaffolding materials and uses thereof |
JP4489975B2 (en) * | 1999-03-30 | 2010-06-23 | ノバルティス アーゲー | Organic compounds |
EP1364663A1 (en) * | 2002-05-21 | 2003-11-26 | Commonwealth Scientific And Industrial Research Organisation | Ocular devices with functionalized surface with adhesive properties |
-
2002
- 2002-05-21 EP EP02011173A patent/EP1364663A1/en not_active Withdrawn
-
2003
- 2003-05-21 US US10/515,164 patent/US20050238692A1/en not_active Abandoned
- 2003-05-21 EP EP03722062A patent/EP1507811A4/en not_active Withdrawn
- 2003-05-21 CN CNB038113996A patent/CN1313557C/en not_active Expired - Fee Related
- 2003-05-21 JP JP2004506426A patent/JP4934279B2/en not_active Expired - Fee Related
- 2003-05-21 EP EP03720028A patent/EP1517970A4/en not_active Withdrawn
- 2003-05-21 CN CNB038115077A patent/CN100506867C/en not_active Expired - Fee Related
- 2003-05-21 WO PCT/AU2003/000611 patent/WO2003097711A1/en active Application Filing
- 2003-05-21 WO PCT/AU2003/000612 patent/WO2003097759A1/en active Application Filing
- 2003-05-21 JP JP2004506383A patent/JP4883907B2/en not_active Expired - Fee Related
- 2003-05-21 CA CA2487041A patent/CA2487041C/en not_active Expired - Fee Related
- 2003-05-21 US US10/515,218 patent/US7479530B2/en not_active Expired - Fee Related
- 2003-05-21 AU AU2003225338A patent/AU2003225338B2/en not_active Ceased
- 2003-05-21 CA CA002487645A patent/CA2487645A1/en not_active Abandoned
- 2003-05-21 AU AU2003229367A patent/AU2003229367B2/en not_active Ceased
Patent Citations (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3185660A (en) * | 1962-08-15 | 1965-05-25 | Du Pont | Stable polymeric dispersions |
US4091165A (en) * | 1971-07-01 | 1978-05-23 | Mitsubishi Petrochemical Co., Ltd. | Surface processing copolymer for synthetic papers |
US4619965A (en) * | 1984-07-19 | 1986-10-28 | Nippon Paint Co., Ltd. | Dispersion stabilizer and its use |
US5470911A (en) * | 1988-11-21 | 1995-11-28 | Collagen Corporation | Glycosaminoglycan-synthetic polymer conjugates |
US5304595A (en) * | 1988-11-21 | 1994-04-19 | Collagen Corporation | Collagen-polymer conjugates |
US5475052A (en) * | 1988-11-21 | 1995-12-12 | Collagen Corporation | Collagen-synthetic polymer matrices prepared using a multiple step reaction |
US5292802A (en) * | 1988-11-21 | 1994-03-08 | Collagen Corporation | Collagen-polymer tubes for use in vascular surgery |
US5476666A (en) * | 1988-11-21 | 1995-12-19 | Collagen Corporation | Glycosaminoglycan-synthetic polymer conjugates |
US5306500A (en) * | 1988-11-21 | 1994-04-26 | Collagen Corporation | Method of augmenting tissue with collagen-polymer conjugates |
US5308889A (en) * | 1988-11-21 | 1994-05-03 | Collagen Corporation | Dehydrated collagen-polymer strings |
US5324775A (en) * | 1988-11-21 | 1994-06-28 | Collagen Corporation | Biologically inert, biocompatible-polymer conjugates |
US5328955A (en) * | 1988-11-21 | 1994-07-12 | Collagen Corporation | Collagen-polymer conjugates |
US5744545A (en) * | 1988-11-21 | 1998-04-28 | Collagen Corporation | Biocompatible adhesive compositions |
US5376375A (en) * | 1988-11-21 | 1994-12-27 | Collagen Corporation | Method of augmenting tissue using collagen-polymer conjugates |
US5510121A (en) * | 1988-11-21 | 1996-04-23 | Rhee; Woonza M. | Glycosaminoglycan-synthetic polymer conjugates |
US5446091A (en) * | 1988-11-21 | 1995-08-29 | Collagen Corporation | Collagen-polymer conjugates containing an ether linkage |
US5786421A (en) * | 1988-11-21 | 1998-07-28 | Cohesion Technologies, Inc. | Method of preventing formation of adhesions following surgery |
US5264214A (en) * | 1988-11-21 | 1993-11-23 | Collagen Corporation | Composition for bone repair |
US5162430A (en) * | 1988-11-21 | 1992-11-10 | Collagen Corporation | Collagen-polymer conjugates |
US5413791A (en) * | 1988-11-21 | 1995-05-09 | Collagen Corporation | Collagen-polymer conjugates |
US5510418A (en) * | 1988-11-21 | 1996-04-23 | Collagen Corporation | Glycosaminoglycan-synthetic polymer conjugates |
US5523348A (en) * | 1988-11-21 | 1996-06-04 | Collagen Corporation | Method of preparing collagen-polymer conjugates |
US5527856A (en) * | 1988-11-21 | 1996-06-18 | Collagen Corporation | Method of preparing crosslinked biomaterial compositions for use in tissue augmentation |
US5543441A (en) * | 1988-11-21 | 1996-08-06 | Collagen Corporation | Implants coated with collagen-polymer conjugates |
US5550188A (en) * | 1988-11-21 | 1996-08-27 | Collagen Corporation | Polymer conjugates ophthalmic devices comprising collagen-polymer conjugates |
US5550187A (en) * | 1988-11-21 | 1996-08-27 | Collagen Corporation | Method of preparing crosslinked biomaterial compositions for use in tissue augmentation |
US5565519A (en) * | 1988-11-21 | 1996-10-15 | Collagen Corporation | Clear, chemically modified collagen-synthetic polymer conjugates for ophthalmic applications |
US5936035A (en) * | 1988-11-21 | 1999-08-10 | Cohesion Technologies, Inc. | Biocompatible adhesive compositions |
US5800541A (en) * | 1988-11-21 | 1998-09-01 | Collagen Corporation | Collagen-synthetic polymer matrices prepared using a multiple step reaction |
US5614587A (en) * | 1988-11-21 | 1997-03-25 | Collagen Corporation | Collagen-based bioadhesive compositions |
US5643464A (en) * | 1988-11-21 | 1997-07-01 | Collagen Corporation | Process for preparing a sterile, dry crosslinking agent |
US5122614A (en) * | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
US5354336A (en) * | 1991-01-29 | 1994-10-11 | Autogenesis Technologies, Inc. | Method for bonding soft tissue with collagen-based adhesives and sealants |
US5573934A (en) * | 1992-04-20 | 1996-11-12 | Board Of Regents, The University Of Texas System | Gels for encapsulation of biological materials |
US5583114A (en) * | 1994-07-27 | 1996-12-10 | Minnesota Mining And Manufacturing Company | Adhesive sealant composition |
US5994133A (en) * | 1995-04-04 | 1999-11-30 | Novartis Ag | Cell growth substrate polymer |
US20010003126A1 (en) * | 1995-10-05 | 2001-06-07 | Rhee Woonza M. | Method of making crosslinked polymer matrices in tissue treatment applications |
US20020042473A1 (en) * | 1995-12-18 | 2002-04-11 | Trollsas Olof Mikael | Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use |
US5874500A (en) * | 1995-12-18 | 1999-02-23 | Cohesion Technologies, Inc. | Crosslinked polymer compositions and methods for their use |
US6864350B2 (en) * | 1996-09-26 | 2005-03-08 | Nektar Therapeutics Al, Corporation | Soluble, degradable poly (ethylene glycol) derivatives for controllable release of bound molecules into solution |
US6232430B1 (en) * | 1996-10-23 | 2001-05-15 | Jds Uniphase Photonics C.V. | Cross-linkers for cross-linkable optical polycarbonates |
US6225367B1 (en) * | 1998-09-15 | 2001-05-01 | Novartis Ag | Polymers |
US6326025B1 (en) * | 1998-12-30 | 2001-12-04 | Depuy Orthopaedics, Inc | Tissue reactive adhesive compositions |
US6428576B1 (en) * | 1999-04-16 | 2002-08-06 | Endospine, Ltd. | System for repairing inter-vertebral discs |
US20070299227A1 (en) * | 1999-07-05 | 2007-12-27 | Achim Gopferich | Biodegradable block copolymers with modifiable surface |
US20020049495A1 (en) * | 2000-03-15 | 2002-04-25 | Kutryk Michael John Bradley | Medical device with coating that promotes endothelial cell adherence |
US20060160957A1 (en) * | 2000-03-24 | 2006-07-20 | Beat Muller | Novel Polymers |
US6844028B2 (en) * | 2001-06-26 | 2005-01-18 | Accelr8 Technology Corporation | Functional surface coating |
US6780942B2 (en) * | 2001-12-20 | 2004-08-24 | Eastman Kodak Company | Method of preparation of porous polyester particles |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110307057A1 (en) * | 2006-04-28 | 2011-12-15 | Leonard Pinchuk | Polymer Adhesive for an Intraocular Lens that Minimizes Posterior Capsule Opacification |
US10555804B2 (en) | 2008-04-04 | 2020-02-11 | Journey1, Inc. | Therapeutic device for pain management and vision |
US20110208300A1 (en) * | 2008-04-04 | 2011-08-25 | ForSight Labs. LLC | Corneal Onlay Devices and Methods |
US9125735B2 (en) * | 2008-04-04 | 2015-09-08 | Forsight Labs, Llc | Method of correcting vision using corneal onlays |
US8409606B2 (en) | 2009-02-12 | 2013-04-02 | Incept, Llc | Drug delivery through hydrogel plugs |
US8563027B2 (en) | 2009-02-12 | 2013-10-22 | Incept, Llc | Drug delivery through hydrogel plugs |
US10596038B2 (en) | 2009-10-23 | 2020-03-24 | Journey1, Inc. | Corneal denervation for treatment of ocular pain |
US10627649B2 (en) | 2009-10-23 | 2020-04-21 | Journey1, Inc. | Conformable therapeutic shield for vision and pain |
US10663761B2 (en) | 2009-10-23 | 2020-05-26 | Journey1, Inc. | Conformable therapeutic shield for vision and pain |
US9707313B2 (en) | 2011-04-13 | 2017-07-18 | Massachusetts Institute Of Technology | Biocompatible adhesive materials and methods |
US8802072B2 (en) | 2011-04-13 | 2014-08-12 | Massachusetts Institute Of Technology | Biocompatible adhesive materials and methods |
US11126011B2 (en) | 2011-04-28 | 2021-09-21 | Journey1, Inc. | Contact lenses for refractive correction |
US10226417B2 (en) | 2011-09-16 | 2019-03-12 | Peter Jarrett | Drug delivery systems and applications |
WO2019222377A3 (en) * | 2018-05-15 | 2020-07-23 | Biodevek, Inc. | Biocompatible adhesive materials with ionic and covalent interaction |
Also Published As
Publication number | Publication date |
---|---|
JP2005526156A (en) | 2005-09-02 |
US7479530B2 (en) | 2009-01-20 |
AU2003229367A1 (en) | 2003-12-02 |
EP1507811A4 (en) | 2008-09-24 |
EP1517970A4 (en) | 2010-11-17 |
US20050228120A1 (en) | 2005-10-13 |
AU2003225338B2 (en) | 2007-09-06 |
EP1364663A1 (en) | 2003-11-26 |
CN1653150A (en) | 2005-08-10 |
WO2003097711A1 (en) | 2003-11-27 |
CN100506867C (en) | 2009-07-01 |
CN1656133A (en) | 2005-08-17 |
EP1507811A1 (en) | 2005-02-23 |
CA2487041C (en) | 2011-03-08 |
JP2005525898A (en) | 2005-09-02 |
EP1517970A1 (en) | 2005-03-30 |
CA2487041A1 (en) | 2003-11-27 |
CN1313557C (en) | 2007-05-02 |
AU2003225338A1 (en) | 2003-12-02 |
CA2487645A1 (en) | 2003-11-27 |
AU2003229367B2 (en) | 2008-02-21 |
WO2003097759A1 (en) | 2003-11-27 |
JP4883907B2 (en) | 2012-02-22 |
JP4934279B2 (en) | 2012-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2003225338B2 (en) | Biomedical adhesive | |
EP1409035B1 (en) | Biomedical moldings | |
US6835410B2 (en) | Bottle-brush type coatings with entangled hydrophilic polymer | |
US7060288B2 (en) | Biomedical devices | |
US20020128346A1 (en) | Hydrogels | |
AU2002251029A1 (en) | Coated biomedical devices | |
JP5009809B2 (en) | Amphiphilic block copolymers and uses thereof | |
Nitschke et al. | Detachment of human endothelial cell sheets from thermo-responsive poly (NiPAAm-co-DEGMA) carriers | |
US20090156745A1 (en) | Surface modified biomedical devices |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: COMMONWEALTH SCIENTIFIC & INDUSTRIAL RESEARCH ORGA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HUGHES, TIMOTHY CHARLES;REEL/FRAME:016748/0101 Effective date: 20050404 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |